Biomarker

Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course

F. Yang, Li, J. Y., Yin, Q. N., Yang, K., Dong, S. N., Bai, L. J., Liu, P., and Tong, X. W., “Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course”, vol. 14, pp. 9655-9666, 2015.

The purposes of this study were to analyze the expression and distribution of human kallikrein 5 (hK5) in triple-negative breast cancer (TNBC) tissues, to establish a standard operating procedure (SOP) for its immunohistochemical assay, and to evaluate the possibility of hK5 being a prognostic biomarker for TNBC. Recombinant hK5 protein and specific antibody were prepared, and the expression and distribution of hK5 in TNBC tissues were detected using immunohistochemistry.

Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: a meta-analysis

S. R. Yan, Liu, Z. J., Yu, S., and Bao, Y. X., “Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: a meta-analysis”, vol. 14, pp. 11573-11586, 2015.

The diagnostic and prognostic value of miR-21 has been examined for hepatocellular carcinoma (HCC), with inconsistent results. Present meta-analysis summarized the diagnostic accuracy and the predictive role for survival of miR-21 in patients with HCC. All eligible studies were searched using PubMed, EMBASE, and Chinese National Knowledge Infrastructure (CNKI) databases up to October 2014. For the diagnostic meta-analysis, the indices of miR-21 in the diagnosis of HCC were pooled using bivariate random-effect approach models.

A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia

D. F. Coutinho, Diniz, C., Filgueiras, R. L. D., Baptista, R. L. R., Ayres-Silva, J. P., Monte-Mór, B. C. R., Bonamino, M. H., and Zalcberg, I. R., “A novel TET2 mutation in a patient with refractory cytopenia with multilineage dysplasia”, vol. 12. pp. 5858-5862, 2013.

Myelodysplastic syndrome diagnosis of karyotypically normal patients may be elusive because it relies exclusively on morphological and clinical data. In routine practice, finding of an acquired mutation or a cytogenetic abnormality provides irrefutable evidence of the clonal nature of that disease. Recurrent deletions and somatic mutations in TET2, a gene involved in epigenetic regulation, have been reported in about 20% of adult patients with myelodysplastic syndrome.

Pages

Subscribe to Biomarker